Validation of peptide mapping for protein identity and genetic stability. Biologics and biotechnology section, pharmaceutical research and manufacturers of America

Biologicals

Volumn 24, Issue 3, 1996, Pages 255-275

  Allen, David ^b   Baffi, Robert ^b   Bausch, James ^b   Bongers, Jacob ^b   Costello, Maureen ^b   Dougherty Jr , John ^b   Federici, Marcia ^b   Garnick, Robert ^a   Peterson, Sydney ^b   Riggins, Ralph ^b   Sewerin, Karin ^b   Tuls, Jody ^b  

^a GENENTECH INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT PROTEIN;

DRUG DEVELOPMENT; GENETIC STABILITY; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN STABILITY; RECOMBINANT DNA TECHNOLOGY; REVIEW;

EID: 0030239194     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1996.0034     Document Type: Article

References (30)

1. 1. International Conference on Harmonisation. Analysis of the expression construct in cells used for production of r-DNA derived protein products. 1995 Nov 29, ICH Tripartite Document, Step 4. Geneva: ICH Secretariat (c/o IFPMA), 1995.
2. 2. International Conference on Harmonisation. Guideline on validation of analytical procedures: definitions and terminology. Fed Regist 1995 (Mar 1); 60: 11260-11262.
3. 3. International Conference on Harmonisation. Validation of analytical procedures: methodology, step 2. The Third International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 1995 Nov 29-Dec 1; Yokohama, Japan. Geneva: ICH Secretariat (c/o IFPMA), 1995.
4. 4. Carr SA, Hemling ME, Bean MF, Roberts GD. Integration of mass spectrometry in analytical biotechnology. Anal Chem 1991; 63: 2802-2824.
5. 5. Ling V, Guzzetta AW, Canova-Davis E et al. Characterization of the tryptic map of recombinant DNA derived tissue plasminogen activator by high-performance liquid chromatography-electrospray ionization mass spectrometry. Anal Chem 1991; 63: 2909-2915.
6. 6. Lewis DA, Guzzetta AW, Hancock WS et al. Characterization of humanized anti-TAC, an antibody directed against the interleukin 2 receptor, using electrospray ionization mass spectrometry by direct infusion, LC/MS and MS/MS. Anal Chem 1994; 66: 585-595.
7. 7. United States Pharmacopeial Convention, Inc. Validation of compendial methods 〈1225〉. In: The United States Pharmacopeia. 23rd rev. Rockville (MD): The Convention, 1994; 1982-1984.
8. 8. Sasaoki K, Hiroshima T, Kusumoto S et al. Oxidation of methionine residues of recombinant human interleukin 2 in aqueous solutions. Chem Pharm Bull 1989; 37: 2160-2164.
9. 9. Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides: succinimide-linked reaçtions that contribute to protein degradation. J Biol Chem 1987; 262: 785-794.
10. 10. Dougherty JJ Jr, Snyder LM, Sinclair RL, Robins RH. High-performance tryptic mapping of recombinant bovine somatotropin. Anal Biochem 1990; 190: 7-20.
11. 11. Shahrokh Z, Eberlein G, Buckley D et al. Major degradation products of basic fibroblast growth factor: detection of succinimide and iso-aspartate in place of aspartate. Pharm Res 1994; 11: 936-944.
12. 12. Dong MW. Tryptic mapping by reversed phase liquid chromatography. Adv Chromatogr 1992; 32: 21-51.
13. 13. Sievert H-JP, Wu S-L, Chloupek R, Hancock, WS. Automated evaluation of tryptic digest from recombinant human growth hormone using ultraviolet spectra and numeric peak information. J Chromatogr 1990; 499: 221-234.
14. 14. Glajch JL, Kirkland JJ, Köhler J. Effect of column degradation on the reversed-phase high-performance liquid chromatographic separation of peptides and proteins. J Chromatogr 1987; 384: 81-90.
15. 15. Malmquist G, Danielsson R. Alignment of chromatographic profiles for principal component analysis: a prerequisite for fingerprinting methods. J Chromatogr 1994; 687: 71-88.
16. 16. Malmquist G. Multivariate evaluation of peptide mapping using the entire chromatographic profile. J Chromatogr 1994; 687: 89-100.
17. 17. Garnick RL. Peptide mapping for detecting variants in protein products. Dev Biol Stand 1991; 76: 117-130.
18. 18. Herold M, Heiger DN, Grimm R. Peptide mapping by reversed-phase HPLC using narrow-bore and microbore columns. Am Lab 1993; (August): 20J-20U.
19. 19. Chloupek RC, Harris RJ, Leonard CK et al. Study of the primary structure of recombinant tissue plasminogen activator by reversed-phase high-performance liquid chromatographic tryptic mapping. J Chromatogr 1989; 463: 375-396.
20. 20. Welinder BS, Kornfelt T, Sørensen HH. Stationary phases: the Achilles heel in HPLC of protein pharmaceuticals? Anal Chem 1995; 67: 39A-43A.
21. 21. Chloupek RC, Battersby JE, Hancock WS. Practical considerations for assessing product quality of biosynthetic proteins by HPLC. In: Mant CT, Hodges RS, editors. High-performance liquid chromatography of peptides and proteins: separation, analysis, and conformation. Boca Raton (FL): CRC Press, 1991:825-833.
22. 22. Hartman PA, Stodola JD, Harbour GC, Hoogerheide JG. Reversed-phase high-performance liquid chromatography peptide mapping of bovine somatotropin. J Chromatogr 1986; 360: 385-395.
23. 23. Committee on Process Development and Manufacturing, Biotechnology Division, Biological Section, Pharmaceutical Manufacturers Association. Assessment of genetic stability for biotechnology products. BioPharm 1991; (February): 22-27.
24. 24. Wiebe ME, Lin NS. Genetic stability of host cell and product. In: Lubiniecki AS, Vargo SA, editors. Regulatory practice for biopharmaceutical production. New York: Wiley-Liss, 1994: 33-62.
25. 25. Lu HS, Tsai LB, Kenney WC, Lai P-H. Identification of unusual replacement of methionine by norleucine in recombinant interleukin-2 produced by E. coli. Biochem Biophys Res Commun 1988; 156: 807-813.
26. 26. Bogosian G, Violand BN, Dorward-King EJ et al. Biosynthesis and incorporation into protein of norleucine by Escherichia coli. J Biol Chem 1989; 264: 531-539
27. 27. Seetharam R, Heeren RA, Wong EY et al. Mistranslation in IGF-1 during over-expression of the protein in Escherichia coli using a synthetic gene containing low frequency codons. Biochem Biophys Res Commun 1988; 155: 518-523.
28. 28. Lu HS, Fausset PR, Sotos LS et al. Isolation and characterization of three recombinant human granulocyte colony stimulating factor His → G1n isoforms produced in Escherichia coli. Protein Expr Purif 1993; 4: 465-472.
29. 29. Harris RJ, Murnane AA, Utter SL et al. Assessing genetic heterogeneity in production cell lines: detection by peptide mapping of a low level Tyr to G1n sequence variant in a recombinant antibody. Biotechnology 1993; 11: 1293-1297.
30. 30. Maiorella BL, Ferris R, Thomson J et al. Evaluation of product equivalence during process optimization for manufacture of human IgM monoclonal antibody. Biologicals 1993; 21: 197-205.